MyBioGate set up a project acceleration team for the T336 project, which is comprised of a team leader, a marketing director, an investment director, and two invited medical imaging experts. Based on the project specifications and goals, the Team formulated two plans: a detailed cross-border acceleration plan and an implementation plan.

1) According to the characteristics of the China market and customer demand, MyBioGate reevaluated its code value and assisted in refining the value points for the market interest.

2) The Team distributed the information to the expert consultant team (comprised of Chinese industrial/life sciences parks, leading healthcare enterprises, investors, and clinical experts) to demonstrate the advantages of the project and attract partnering intentions.

1). Put forward advice and sharpened the business plan, withthe specific content is as follows:

– Focused on core team members’ strength; showcased prominent team background

– Complete China market plans to suit the actual market demand and strategy

– Highlight core technology/advantages in comparison with the current technology/products

2) Proposed improvements

The acceleration team conducted comprehensive technical and market research for T336 and received feedback from experts in the field. The Team advised the project to revise its original business plan and strategic approach based on the needs of the China market.  The Team then thoroughly formulated and improved the implementation plan with the project.

– The Team organized in-person 1-on-1 partnering meetings for the project with the top-tier industrial and life sciences parks such as Nanjing, Suzhou, and Changzhou.

– The Team also arranged to participate in the MyBioGate China Focus conferences to meet with Chinese companies in various locations.

– The Team then did a detailed competitive analysis in regards to policy advantages, and a regional vertical market analysis suggestion report.

– Based on the vertical market environment, medical resources, human resources, and local supportive policies, the Team recommended Suzhou (Taicang) as the best location for the project.

– After complete hands-on support and acceleration service, T336 finally raised funds from MyBioGate Fund, Jiangsu Industrial Technology Research Institute (JITRI), and Taicang Biomedical Industry Fund, and is landing in Suzhou (Taicang) by August 2020.

– Based on the vertical market environment, medical resources, human resources, and local supportive policies, the Team recommended Suzhou (Taicang) as the best location for the project.
– After complete hands-on support and acceleration service, T336 finally raised funds from MyBioGate Fund, Jiangsu Industrial Technology Research Institute (JITRI), and Taicang Biomedical Industry Fund, and is landing Suzhou(Taicang) in August 2020.

 Achievements:

• Obtained 45 million-yuan ($6.43 million USD) investment from the MyBioGate Fund, Jiangsu Industrial Technology Research Institute (JITRI), and Taicang Biomedical Industry Fund.
• The project expected to land in Jiangsu by August 2020, with a 10,000-square-foot.  office and factory space.
• Clinical research supported by Grade A hospitals in China.
• Established a professional marketing team for product registration, certification, as well as sales channel establishment.